Skip to content

Incanthera PLC - Proactive Investor Forum Presentation


Announcement provided by

Incanthera plc · INC

16/10/2025 10:15

Incanthera PLC - Proactive Investor Forum Presentation
RNS Number : 6763D
Incanthera PLC
16 October 2025
 

Goal Group

 

                                                                                16 October 2025

 

Incanthera plc

("Incanthera" the "Company")

Investor Presentation

 

Proactive Investor Forum Presentation

 

Incanthera plc (AQSE:INC), the company specially focussed on innovative technologies in dermatology and oncology, advises that following their presentation at Proactive investor's One2One Biotech Investor Forum in London on 9 October 2025, the recording of the company's presentation is now available on the following link:

 

https://www.youtube.com/embed/mMnfpaj1ZCE?si=pikzFDks4YpOQ_En

 

This is also available to view on the Company's website, along with the investor presentation, given on the evening, at https://www.incanthera.com/investors/results-reports-and-presentations/.

 

 

RNS Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature.

 

For further enquiries:

 

  Incanthera plc:                                                                                                                                                                 

www.incanthera.com

 

Tim McCarthy, Chairman

tim.mccarthy@incanthera.com

 

Simon Ward, Chief Executive Officer

simon.ward@incanthera.com

 

Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com

 

 

+44 (0) 7831 675747

 

 

+44 (0) 7747 625506

 

 

+44 (0) 7776 234600



Broker: 

Stanford Capital Partners Ltd

Patrick Claridge / Bob Pountney               

+44 (0) 20 3650 3650/51

 

Notes to Editors

 

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford.  Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

                                                                                                                

For more information on the Company please visit: www.incanthera.com

 

@incantheraplc

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUNRKRVBURARA]]>

View more ...

INC announcementsAll announcements

Company

  • About
  • News
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2025. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal